Panavir, ampoules 0.004%, 5ml, 5pcs

Composition

Active ingredient:

panavir® (polysaccharides of Solanum tuberosum shoots) 200 mcg;

Auxiliary substances:

sodium chloride — 0.045 g;

water for injection-up to 5 ml;

Pharmacological action

Panavir® is a purified extract of Solanum tuberosum plant shoots; the main Active ingredient is a hexose glycoside consisting of glucose, rhamnose, arabinose, mannose, xylose, galactose, and uronic acids.

Panavir ® is an antiviral and immunomodulatory agent. Increases the body’s non-specific resistance to various infections and promotes the induction of interferons alpha and gamma by blood leukocytes.

In therapeutic doses, the drug is well tolerated.

Tests have shown the absence of mutagenic, teratogenic, carcinogenic, allergenic and embryotoxic effects. In preclinical studies on laboratory animals, a negative effect on the reproductive function and development of the fetus was not established.

It has anti-inflammatory properties in experimental models of exudative edema, chronic proliferative inflammation and in the test of pseudoallergic inflammatory response to concanavalin A.

Analgesic effect was shown on models of neurogenic pain and pain caused by the inflammatory process and thermal irritation.

It has an antipyretic effect.

Neuroprotective properties are shown on the model of Parkinsonian syndrome caused by systemic use of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

It has the ability to improve the function of the retina and optic nerve.

It has wound-healing properties in the model of gastric ulcer.

Pharmacokinetics

Solution for intravenous use. When administered intravenously, polysaccharides are detected in the blood as early as 5 minutes after use, and are captured by cells of the reticuloendothelial system of the liver and spleen. Elimination begins quickly, after 20-30 minutes polysaccharides are detected in the urine and exhaled air.

Indications

• herpesvirus infections of various localization, including recurrent genital herpes, herpes zoster and ophthalmic herpes;
• secondary immunodeficiency states against the background of infectious diseases;
• cytomegalovirus infection, including in patients with habitual miscarriage. Can be used in women with chronic viral infection and interferonogenic condition at the stage of preparation for pregnancy;
• human papillomavirus infection (anogenital warts) — as part of complex therapy;
• ulcer disease of stomach and duodenum in patients with long-nerubayskoe ulcers, symptomatic ulcers of the gastroduodenal zone in the complex therapy;
• tick — borne encephalitis- with the aim of reducing viral load and relieve neurological symptoms (entrelace, decreased reflexes, pain exit points of cranial nerves, nystagmus) – as part of complex therapy;
• rheumatoid arthritis in combination with herpesvirus infection in immunocompromised patients (to enhance the analgesic and anti-inflammatory effect of the main therapy) – as part of complex therapy;
• acute respiratory viral infections and influenza — as part of complex therapy;
• chronic bacterial prostatitis — as part of complex therapy.

Use during pregnancy and lactation

Use during pregnancy is only possible if the intended benefit to the mother outweighs the potential risk to the fetus.

If it is necessary to use the drug during lactation, breastfeeding should be discontinued for the duration of the drug.

Contraindications

• individual intolerance;
• allergy to the components of the drug: glucose, mannose, rhamnose, arabinose, xylose;
• lactation period;
• children under 12 years of age.

Side effects

The drug is well tolerated, possible complications may be associated with individual intolerance and hypersensitivity to the components of the drug.

Interaction

Not detected.

How to take, course of use and dosage

In / in a jet slowly. The therapeutic dose of the drug is 200 micrograms of the Active ingredient (contents of 1 ampoule or 1 bottle).

For the treatment of herpesvirus infections and tick-borne encephalitis, it is used twice with an interval of 48 or 24 hours. If necessary, the course of treatment can be repeated after 1 month.

For the treatment of cytomegalovirus and papillomavirus infections, it is used three times during the first week with an interval of 48 hours and twice during the second week with an interval of 72 hours.

For the treatment of peptic ulcer of the stomach and duodenum in the acute phase and symptomatic ulcers of the gastroduodenal zone,5 intravenous injections are used every other day for 10 days.

For the treatment of rheumatoid arthritis in combination with herpesvirus infection in immunocompromised patients,5 intravenous injections are used at intervals of 24-48 hours, if necessary, the course can be repeated after 2 months.

For the treatment of acute respiratory viral infections and influenza,2 intravenous injections are used with an interval of 18-24 hours.

For the treatment of patients with chronic bacterial prostatitis,5 intravenous injections are used with an interval of 48 hours.

Use in pediatrics: Panavir® it is prescribed to children from 12 years of age at a dose of 100 mcg iv 1 time a day. For the treatment of herpesvirus infections and tick-borne encephalitis, it is used twice with an interval of 48 or 24 hours. If necessary, the course of treatment can be repeated after 1 month. For the treatment of cytomegalovirus and papillomavirus infections, it is used three times during the first week with an interval of 48 hours and twice during the second week with an interval of 72 hours.

Overdose

No overdose cases have been reported. The results of preclinical studies indicate low toxicity of the drug.

Special instructions

when used at the stage of preparation for pregnancy helps to reduce the frequency of reproductive losses in cytomegalovirus and herpesvirus infections.

If the solution becomes cloudy, the drug is considered unsuitable for use.

Form of production

Solution for intravenous use

Storage conditions

In a dark place, at a temperature of 2-25 °C

Shelf life

3 years

Active ingredient

Extract of potato shootsra.

Conditions of release from pharmacies

By prescription

Dosage form

solution for infusions

Description

For adults as directed by your doctor

Indications

Cytomegalovirus infection, Immunodeficiency states, Herpes